Brind.

Analyst reiterated a Buy rating on PROCEPT BioRobotics on August 14, 2025.

1 report, 1 independent Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Analyst reiterated a Buy rating on PROCEPT BioRobotics on August 14, 2025.

Who's involved

What this event is mainly about
PROCEPT BioRobotics

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyLeerink Partners Reiterates a Buy Rating on PROCEPT BioRobotics (PRCT) PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the best medical device stocks to buy according to analysts. On August 8